Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
25702091
DOI
10.1007/s13277-015-3249-x
PII: 10.1007/s13277-015-3249-x
Knihovny.cz E-resources
- MeSH
- Adenocarcinoma drug therapy genetics pathology MeSH
- Quinazolines administration & dosage MeSH
- ErbB Receptors antagonists & inhibitors genetics MeSH
- Erlotinib Hydrochloride MeSH
- Gefitinib MeSH
- Protein Kinase Inhibitors administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Mutation MeSH
- Carcinoma, Non-Small-Cell Lung drug therapy genetics pathology MeSH
- Disease-Free Survival MeSH
- Prognosis MeSH
- Proto-Oncogene Proteins p21(ras) MeSH
- Proto-Oncogene Proteins genetics MeSH
- ras Proteins genetics MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Quinazolines MeSH
- EGFR protein, human MeSH Browser
- ErbB Receptors MeSH
- Erlotinib Hydrochloride MeSH
- Gefitinib MeSH
- Protein Kinase Inhibitors MeSH
- KRAS protein, human MeSH Browser
- Proto-Oncogene Proteins p21(ras) MeSH
- Proto-Oncogene Proteins MeSH
- ras Proteins MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors MeSH
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) represent novel effective agents approved for the treatment of patients with advanced-stage NSCLC. KRAS mutations have been reported as a negative prognostic and predictive factor in patients with NSCLC treated with EGFR-TKIs. Several studies have recently shown that statins can block tumour cell growth, invasion and metastatic potential. We analysed clinical data of 67 patients with locally advanced (IIIB) or metastatic stage (IV) NSCLC harbouring Kirsten rat sarcoma viral oncogene (KRAS) mutation treated with erlotinib or gefitinib. Twelve patients were treated with combination of EGFR-TKI and statin and 55 patients were treated with EGFR-TKI alone. Comparison of patients' survival (progression-free survival (PFS) and overall survival (OS)) according to the treatment used was performed using the Gehan-Wilcoxon test. The median of PFS and OS for patients treated with EGFR-TKI alone was 1.0 and 5.4 months compared to 2.0 and 14.0 months for patients treated with combination of EGFR-TKI and statin (p = 0.025, p = 0.130). In conclusion, the study results suggest significant improvement of PFS for patients treated with combination of statin and EGFR-TKI, and the difference in OS was not significant.
See more in PubMed
Nature. 1990 Feb 1;343(6257):425-30 PubMed
Curr Opin Oncol. 2001 Nov;13(6):491-8 PubMed
J Thorac Oncol. 2010 Aug;5(8):1175-84 PubMed
J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 PubMed
Anticancer Res. 2010 Dec;30(12):5121-8 PubMed
Clin Cancer Res. 2011 Mar 15;17(6):1553-60 PubMed
Clin Cancer Res. 1996 Mar;2(3):483-91 PubMed
Cancer Genet. 2013 Jan-Feb;206(1-2):26-31 PubMed
Invest New Drugs. 2010 Dec;28(6):791-9 PubMed
Cancer Lett. 2001 Sep 28;171(1):1-10 PubMed
Neoplasia. 2009 Oct;11(10):1084-92 PubMed
Neoplasma. 2013;60(1):26-32 PubMed
Eur Respir J. 2001 Dec;18(6):1059-68 PubMed
Cell Death Dis. 2013 Sep 26;4:e814 PubMed
J Clin Oncol. 2005 Sep 1;23(25):5900-9 PubMed
Nature. 2008 Oct 23;455(7216):1069-75 PubMed
J Thorac Oncol. 2006 Jan;1(1):7-9 PubMed
Curr Opin Investig Drugs. 2009 Dec;10 (12 ):1305-14 PubMed
Lancet Oncol. 2001 Sep;2(9):533-43 PubMed
Ann Surg Oncol. 2010 Apr;17 (4):1168-76 PubMed
Cancer Res. 1991 Jul 1;51(13):3602-9 PubMed
Clin Cancer Res. 2003 Jan;9(1):10-9 PubMed
Nat Rev Cancer. 2003 Jun;3(6):459-65 PubMed
J Clin Oncol. 2002 Jan 1;20(1):110-24 PubMed
Leukemia. 2002 Apr;16(4):508-19 PubMed
